Literature DB >> 16828440

Inhaled carbon monoxide inhibits intimal hyperplasia and provides added benefit with nitric oxide.

Kathleen G Raman1, Joel E Barbato, Emeka Ifedigbo, Brett A Ozanich, Mazen S Zenati, Leo E Otterbein, Edith Tzeng.   

Abstract

OBJECTIVE: Carbon monoxide (CO) and nitric oxide (NO) have both been shown to possess vasoprotective properties. NO has successfully inhibited intimal hyperplasia in both small-animal and large-animal experimental models, whereas CO has only been studied in rodents. Evidence suggests that these two molecules may exert their vascular effects through common as well as unique signaling pathways. The purpose of this study was to determine the effect of a low concentration of inhaled CO on intimal hyperplasia in a large-animal model and if CO and NO treatment could exert a synergistic effect to inhibit this process.
METHODS: Balloon angioplasty was performed in a porcine model. Animals received inhaled CO (250 ppm) delivered preoperatively for 60 minutes or preoperatively and intraoperatively. Blood was collected for carboxyhemoglobin (COHgb) measurements at the start of the operation and every 30 minutes during the operation. Heart rate, respiratory rate, and oxygen saturation were monitored throughout. To study the effect of combined CO and NO treatment, another group of pigs received inducible NO synthase (iNOS) gene transfer in one iliac artery and control gene transfer (AdlacZ) in the contralateral iliac artery, with or without preoperative and intraoperative inhaled CO. Adenoviral infection was performed immediately after balloon injury. All animals were euthanized at 3 weeks, and iliac arteries were collected for histologic and morphometric analysis.
RESULTS: One hour of pretreatment with CO was associated with modest and transient elevations in COHgb levels, resulting in a 25.6% reduction in neointimal area and a 10% reduction in intimal area/medial area ratio (I/M) 3 weeks after injury (NS). In contrast, preoperative followed by intraoperative CO administration increased COHgb in a sustained fashion and inhibited neointima formation by 51.7% and I/M by 31% (P < .001). There was no evidence of toxicity associated with this administration of CO. The treatment of injured iliac arteries with the control adenoviral vector AdlacZ did not further increase the inhibitory effect of CO on intimal hyperplasia. The combination of inhaled CO and iNOS gene transfer resulted in greater protection, however, with a 64% reduction in neointimal area and a 48% reduction in I/M (P < .001).
CONCLUSIONS: CO is an effective means of reducing intimal hyperplasia in large animals after vascular injury when delivered during the operative procedure. No toxicity was associated with the increase in COHgb. The combination of CO and NO provided additional protection against the vascular injury response, with a greater reduction in neointima formation. These data suggest that these agents may prove to be clinically beneficial in prolonging vascular patency after interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828440     DOI: 10.1016/j.jvs.2006.04.004

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

Review 1.  Toward Carbon Monoxide-Based Therapeutics: Critical Drug Delivery and Developability Issues.

Authors:  Xingyue Ji; Krishna Damera; Yueqin Zheng; Bingchen Yu; Leo E Otterbein; Binghe Wang
Journal:  J Pharm Sci       Date:  2016-01-06       Impact factor: 3.534

Review 2.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

3.  Delayed inhaled carbon monoxide mediates the regression of established neointimal lesions.

Authors:  Michael Madigan; Fateh Entabi; Brian Zuckerbraun; Patricia Loughran; Edith Tzeng
Journal:  J Vasc Surg       Date:  2014-01-11       Impact factor: 4.268

4.  Carbon Monoxide Inhibits Islet Apoptosis via Induction of Autophagy.

Authors:  Do-Sung Kim; Lili Song; Jingjing Wang; Hongju Wu; Wenyu Gou; Wanxing Cui; Jae-Sung Kim; Hongjun Wang
Journal:  Antioxid Redox Signal       Date:  2017-11-27       Impact factor: 8.401

Review 5.  The therapeutic potential of carbon monoxide.

Authors:  Roberto Motterlini; Leo E Otterbein
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

6.  Systemic vasoprotection by inhaled carbon monoxide is mediated through prolonged alterations in monocyte/macrophage function.

Authors:  Andrew Leake; Karim Salem; Michael C Madigan; Ghee Rye Lee; Ankur Shukla; Guiying Hong; Brian S Zuckerbraun; Edith Tzeng
Journal:  Nitric Oxide       Date:  2019-10-05       Impact factor: 4.427

7.  Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts.

Authors:  Atsunori Nakao; Chien-Sheng Huang; Donna B Stolz; Yinna Wang; Jonathan M Franks; Naobumi Tochigi; Timothy R Billiar; Yoshiya Toyoda; Edith Tzeng; Kenneth R McCurry
Journal:  Cardiovasc Res       Date:  2010-09-16       Impact factor: 10.787

8.  Organic CO Prodrugs: Structure-CO-Release Rate Relationship Studies.

Authors:  Zhixiang Pan; Vayou Chittavong; Wei Li; Jun Zhang; Kaili Ji; Mengyuan Zhu; Xingyue Ji; Binghe Wang
Journal:  Chemistry       Date:  2017-07-04       Impact factor: 5.236

9.  My Continuing Evolution as a Surgeon-Scientist: A Decade after the Jacobson Promising Investigator Award.

Authors:  Edith Tzeng
Journal:  J Am Coll Surg       Date:  2016-10-08       Impact factor: 6.113

10.  Biliverdin protects against liver ischemia reperfusion injury in swine.

Authors:  Barbara Andria; Adele Bracco; Chiara Attanasio; Sigismondo Castaldo; Maria Grazia Cerrito; Santolo Cozzolino; Daniele Di Napoli; Roberto Giovannoni; Antonio Mancini; Antonino Musumeci; Ernesto Mezza; Mario Nasti; Vincenzo Scuderi; Stefania Staibano; Marialuisa Lavitrano; Leo E Otterbein; Fulvio Calise
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.